Sanofi India Limited has received an acceptance order from the Asst. State Tax Officer, Thripunithura, Kerala, dropping scrutiny proceedings initiated for the financial year 2020-21. The order, dated May 25, 2026, and received on May 26, 2026, accepts the submissions made by the company regarding alleged tax discrepancies. There is no material impact on the financial, operational, or other activities of the company as a result of this order.

The scrutiny proceedings were initiated to verify a tax amount of INR 59,77,141. The verification focused on discrepancies related to the generation of multiple e-way bills, non-generation of e-way bills, e-way bills not reported in GST returns, and excess input tax credit availed. The authority has now dropped these proceedings after accepting the company's submissions.

Details of the Order

The disclosure was made to the stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The key details of the order are summarized below:

The company confirmed that the order resolves the proceedings initiated for the verification of the specified tax amount. The acceptance of the submissions by the tax authority concludes the scrutiny process for the period in question.

Sanofi India Limited has published its financial results for the quarter ended March 31, 2026, in compliance with SEBI regulations. The company reported total income from operations of ₹4,767 million for the period, with net profit after tax standing at ₹1,026 million and net profit before tax reaching ₹1,379 million. The basic and diluted earnings per share for the quarter were recorded at ₹44.55 each, based on a face value of ₹10 per share.

Regulatory Compliance and Publication

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sanofi India Limited published its financial results in Business Standard (English) and Sakal (Marathi) newspapers on April 29, 2026. The company notified both BSE Limited and The National Stock Exchange of India Limited about this newspaper publication through official communication signed by Haresh Vala, Company Secretary and Compliance Officer.

Financial Performance Analysis

The company's total comprehensive income for the quarter ended March 31, 2026, was ₹1,026 million. Equity share capital remained constant at ₹230 million across all reported periods. The reserves (excluding revaluation reserve) as shown in the audited balance sheet of the previous year stood at ₹7,262 million for the year ended December 31, 2025.

Quarterly Performance Comparison

When compared with the previous quarter ended December 31, 2025, Sanofi India showed improvement in several key metrics. Total income from operations increased from ₹4,226 million in Q3 FY26 to ₹4,767 million in Q4 FY26. Net profit after tax also rose from ₹617 million to ₹1,026 million during the same period. However, compared with the corresponding quarter of the previous year ended March 31, 2025, total income declined from ₹5,392 million, while net profit after tax decreased from ₹1,195 million.

Board Approval and Compliance

The financial results for the quarter ended March 31, 2026, have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on April 28, 2026. The results have been prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013, read together with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India.

Source: None/Company/INE058A01010/621e5010f2044c32.pdf